Effectiveness and Safety of SGLT2 Inhibitor Treatment on Renal Outcomes in Patients with Type 2 Diabetes: A Nationwide Observational Cohort Study in South Korea

被引：0
|
作者：
Chang, Junhyuk [1 ]
Kim, Chungsoo [1 ]
Choi, Heejung [2 ]
Park, Rae Woong [1 ]
Lee, Sukhyang [3 ]
机构：
[1] Ajou Univ, Dept Biomed Sci, Grad Sch Med, Suwon, South Korea
[2] Ajou Univ, Dept Nephrol, Sch Med, Suwon, South Korea
[3] Ajou Univ, Div Clin Pharm, Coll Pharm, Suwon, South Korea
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2024年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
1151
引用
收藏
页码：516 / 516
页数：1
相关论文
共 50 条
  • [41] Relationship between SGLT2 Inhibitor, ACEI/ARB, and Pioglitazone to Renal Function in Patients with Type 2 Diabetes Mellitus
    Lee, Tao-Chun
    DIABETES, 2020, 69
  • [42] The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
    McGill, Janet B.
    DIABETES THERAPY, 2014, 5 (01) : 43 - 63
  • [43] Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
    Peppa, Melpomeni
    Manta, Aspasia
    Mavroeidi, Ioanna
    Asimakopoulou, Athina
    Syrigos, Alexandros
    Nastos, Constantinos
    Pikoulis, Emmanouil
    Kollias, Anastasios
    PHARMACEUTICS, 2023, 15 (11)
  • [44] The SGLT2 Inhibitor Empagliflozin for the Treatment of Type 2 Diabetes Mellitus: a Bench to Bedside Review
    Janet B. McGill
    Diabetes Therapy, 2014, 5 : 43 - 63
  • [45] COST-EFFECTIVENESS OF SGLT2 INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES AND ITS COMPLICATIONS
    Igarashi, Ataru
    Tachimori, Hisateru
    Maruyama-Sakurai, Keiko
    Kubota, Anna
    Segawa, Yasumasa
    Akiyama, Hiroki
    Imai, Naohiko
    Kohsaka, Shun
    Miyata, Hiroaki
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I525 - I525
  • [46] Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study
    Singh, Lakshmi G.
    Ntelis, Spyridon
    Siddiqui, Tariq
    Seliger, Stephen L.
    Sorkin, John D.
    Spanakis, Elias K.
    DIABETES CARE, 2024, 47 (06) : 933 - 940
  • [47] THE SGLT2 INHIBITOR DAPAGLIFLOZIN IMPROVES ERECTILE DYSFUNCTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A PROSPECTIVE STUDY
    Cannarella, Rossella
    Condorelli, Rosita A. Angela
    Leanza, Claudia
    Garofalo, Vincenzo
    Lundy, Scott
    Calogero, Aldo E.
    La Vignera, Sandro
    FERTILITY AND STERILITY, 2023, 120 (04) : E245 - E246
  • [48] Cost-Effectiveness of DPP-4 Inhibitor and SGLT2 Inhibitor Combination Therapy for Type 2 Diabetes
    Pawaskar, Manjiri
    Bilir, S. Pinar
    Kowal, Stacey
    Gonzalez, Claudio
    Rajpathak, Swapnil
    Davies, Glenn
    AMERICAN JOURNAL OF MANAGED CARE, 2019, 25 (05): : 231 - +
  • [49] Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study
    Dennis, John M.
    Young, Katherine G.
    McGovern, Andrew P.
    Mateen, Bilal A.
    Vollmer, Sebastian J.
    Simpson, Michael D.
    Henley, William E.
    Holman, Rury R.
    Sattar, Naveed
    Pearson, Ewan R.
    Hattersley, Andrew T.
    Jones, Angus G.
    Shields, Beverley M.
    LANCET DIGITAL HEALTH, 2022, 4 (12): : E873 - E883
  • [50] Development of a treatment selection algorithm for SGLT2 and DPP-4 inhibitor therapies in people with type 2 diabetes: a retrospective cohort study
    Dennis, John M
    Young, Katherine G
    McGovern, Andrew P
    Mateen, Bilal A
    Vollmer, Sebastian J
    Simpson, Michael D
    Henley, William E
    Holman, Rury R
    Sattar, Naveed
    Pearson, Ewan R
    Hattersley, Andrew T
    Jones, Angus G
    Shields, Beverley M
    The Lancet Digital Health, 2022, 4 (12)
12345